<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00191646</url>
  </required_header>
  <id_info>
    <org_study_id>6891</org_study_id>
    <secondary_id>B9E-US-S302</secondary_id>
    <nct_id>NCT00191646</nct_id>
  </id_info>
  <brief_title>An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy</brief_title>
  <official_title>Phase III Randomized Trial of Induction Chemotherapy With Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients With Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III randomized study comparing induction treatments of Gemcitabine and
      Carboplatin versus Paclitaxel and Carboplatin, with or without consolidation therapy for
      patients that do not have any evidence of disease after completion of six cycles of induction
      therapy. Patients with disease after induction therapy will crossover to receive single agent
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study (Study B9E-US-S302) is a multicenter, comparative, open-label randomized,
      superiority, trial evaluating Gemcitabine and Carboplatin to the standard of care. Both
      treatment arms will be given the option to receive elective consolidation therapy of
      Paclitaxel 135 mg/m^2 given every 28 days for one year. Patients not achieving a complete
      response will crossover to the opposite single agent.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to measured progressive disease or death up to 82 months</time_frame>
    <description>Progression free survival was defined as the duration from the date of randomization to the first date of documented disease progression or death from any cause. Tumor assessments were performed every three 21-day cycles during induction and crossover. Progression free survival was censored at the date of the last follow-up visit for participants who were still alive and who had not progressed. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Response (Response Rate)</measure>
    <time_frame>Baseline to measured progressive disease up to 82 months</time_frame>
    <description>Response rate (RR) = proportion of participants with best overall Complete Response (CR: disappearance of all target lesions [TL]) or Partial Response (PR: 30% decrease in sum of longest diameter of TL). Induction therapy RR = number of participants with CR or PR during induction divided by number of participants with measurable disease at baseline (TL measurement during screening). Crossover therapy RR = number of participants with CR or PR during crossover divided by number of participants with measurable disease at baseline (latest TL measurement by first dose date of crossover therapy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>Baseline to stopping treatment up to 82 months</time_frame>
    <description>Time to treatment failure was defined as the duration from date of randomization to the date of the first of the following events: early discontinuation of study therapy; progression of disease, or death due to any cause. Time to treatment failure will be censored at the date of the last follow-up visit for participants who did not discontinue early, who are still alive, and who have not progressed. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Baseline to death from any cause up to 82 months</time_frame>
    <description>Overall survival is defined as the duration from baseline to death. For participants who are still alive at the data cut-off date, survival will be censored at the last contact date. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">919</enrollment>
  <condition>Genital Neoplasms, Female</condition>
  <condition>Fallopian Tube Neoplasms</condition>
  <condition>Ovarian Neoplasms</condition>
  <condition>Pelvic Neoplasms</condition>
  <condition>Peritoneal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Gemcitabine/Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine 1000 milligrams per meter square (mg/m^2) Day 1 and Day 8, Carboplatin Area Under the Curve (AUC) 5 Day 1, six 21-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel/Carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 175 milligrams per meter square (mg/m^2) administered intravenously (IV) Day 1 Carboplatin AUC 6 Day 1, six 21 day cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m^2, Intravenously (IV), day 1 and day 8 every (q) 21 days x 6 cycles
If anything other than complete response in Paclitaxel arm patients, 1000 mg/m^2, IV, day 1 and day 8 q 21 days until complete response, disease progression or unacceptable toxicity</description>
    <arm_group_label>Gemcitabine/Carboplatin</arm_group_label>
    <other_name>LY188011</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175 mg/m^2, IV, Day 1, q 21 days x 6 cycles
If complete response both Paclitaxel and Gemcitabine arms may elect to receive consolidation therapy, 135 mg/m^2, IV, 3 hours q 28 days x 12 cycles (1 year)
If no complete response, then Gemcitabine arm patients may receive 175 mg/m^2, IV, Day 1, q 21 days until complete response, disease progression or unacceptable toxicity</description>
    <arm_group_label>Paclitaxel/Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles
Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles</description>
    <arm_group_label>Gemcitabine/Carboplatin</arm_group_label>
    <arm_group_label>Paclitaxel/Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Patients with a histologic diagnosis of primary peritoneal carcinoma, epithelial
             ovarian carcinoma or fallopian tube carcinoma Stage IC, II, III or IV.

          -  All patients must have had surgery for fallopian, ovarian or peritoneal carcinoma to
             establish the diagnosis and have tissue available for histologic evaluation and
             confirmation of organ of origin.

          -  Patients must be enrolled no more than twelve weeks postoperatively.

          -  Patients must be willing to receive their chemotherapy drugs intravenously, as
             intraperitoneal therapy is not part of this trial.

        Key Exclusion Criteria:

          -  Patients with a current diagnosis of epithelial ovarian tumor of low malignant
             potential (Borderline carcinomas) are not eligible.

          -  Patients who have received prior radiotherapy to any portion of the abdominal cavity
             or pelvis are excluded

          -  Patients who have received prior chemotherapy for any abdominal or pelvic tumor are
             excluded

          -  With the exception of non-melanoma skin cancer and other specific malignancies
             patients who had (or have) any evidence of the other cancer present within the last 5
             years or whose previous cancer treatment contraindicates this protocol therapy are
             excluded.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) OR 1-317-615-4559 MON-FRI 9AM -5PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <zip>95032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <zip>95350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33323</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palatine</city>
        <state>Illinois</state>
        <zip>60067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dunmore</city>
        <state>Pennsylvania</state>
        <zip>18512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <zip>15905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78735</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>009362712</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <results_first_submitted>August 12, 2010</results_first_submitted>
  <results_first_submitted_qc>August 12, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2010</results_first_posted>
  <last_update_submitted>February 28, 2011</last_update_submitted>
  <last_update_submitted_qc>February 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Genital Neoplasms, Female</mesh_term>
    <mesh_term>Pelvic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>919 patients were randomized, only 831 randomized patients were included in any analyses. 85 randomized patients were excluded due to significant noncompliant issues and 3 patients were excluded due to unavailable data.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gemcitabine/Carboplatin</title>
          <description>Induction: Gemcitabine 1000 mg/m^2 Days 1 and 8 followed by Carboplatin Area Under the Curve (AUC) 5 Day 1; every 21-days.
Consolidation (gemcitabine to paclitaxel): Paclitaxel 135 mg/m^2 Intravenous Piggy-Back (IVPB), 3 hours every 28 days for 12 cycles (one year).
Paclitaxel (crossover): Single agent Paclitaxel 175 mg/m^2 day 1 to be repeated every 21 days.</description>
        </group>
        <group group_id="P2">
          <title>Paclitaxel/Carboplatin</title>
          <description>Induction: Paclitaxel 175 mg/m^2 and Carboplatin AUC 6 Day 1, every 21 days. Consolidation (paclitaxel to paclitaxel): Paclitaxel 135 mg/m^2 IVPB, 3 hours every 28 days for 12 cycles (one year).
Gemcitabine (crossover): Single agent Gemcitabine 1000 mg/m^2 days 1, 8 to be repeated every 21 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="417"/>
                <participants group_id="P2" count="414"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Induction Therapy</title>
              <participants_list>
                <participants group_id="P1" count="411"/>
                <participants group_id="P2" count="409"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Consolidation Therapy</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Crossover Therapy</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="246">Completed was defined as the patients treated in either consolidation therapy or crossover therapy.</participants>
                <participants group_id="P2" count="261">Completed was defined as the patients treated in either consolidation therapy or crossover therapy.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing Data</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gemcitabine/Carboplatin</title>
          <description>Induction: Gemcitabine 1000 mg/m^2 Days 1 and 8 followed by Carboplatin Area Under the Curve (AUC) 5 Day 1; every 21-days.
Consolidation (gemcitabine to paclitaxel): Paclitaxel 135 mg/m^2 Intravenous Piggy-Back (IVPB), 3 hours every 28 days for 12 cycles (one year).
Paclitaxel (crossover): Single agent Paclitaxel 175 mg/m^2 day 1 to be repeated every 21 days.</description>
        </group>
        <group group_id="B2">
          <title>Paclitaxel/Carboplatin</title>
          <description>Induction: Paclitaxel 175 mg/m^2 and Carboplatin AUC 6 Day 1, every 21 days. Consolidation (paclitaxel to paclitaxel): Paclitaxel 135 mg/m^2 IVPB, 3 hours every 28 days for 12 cycles (one year).
Gemcitabine (crossover): Single agent Gemcitabine 1000 mg/m^2 days 1, 8 to be repeated every 21 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="417"/>
            <count group_id="B2" value="414"/>
            <count group_id="B3" value="831"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.7" spread="11.4"/>
                    <measurement group_id="B2" value="60.3" spread="10.8"/>
                    <measurement group_id="B3" value="60.0" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="417"/>
                    <measurement group_id="B2" value="414"/>
                    <measurement group_id="B3" value="831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="379"/>
                    <measurement group_id="B2" value="379"/>
                    <measurement group_id="B3" value="758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Organ of Origin</title>
          <description>Organ from which disease originated</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ovary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="355"/>
                    <measurement group_id="B2" value="362"/>
                    <measurement group_id="B3" value="717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peritoneum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Extent of Residual Disease</title>
          <description>Patients either had no clinical evidence of residual disease (non-measurable), either by physical or radiologic exam, that was measurable as defined below or they had residual disease that was measured by either of the following techniques. Measurable lesions were those which could be measured accurately and followed in at least one dimension (the longest dimension being the one recorded). Each lesion must be &gt;= 20 millimeters (mm) when measured by conventional techniques [palpation, plain X-ray, Computed tomography (CT), and Magnetic resonance imaging (MRI)], or &gt;= 10 mm by spiral CT.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Measurable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-measurable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Zubrod Performance Status</title>
          <description>0 Asymptomatic
Symptomatic, fully ambulatory
Symptomatic, in bed &lt; 50% of the day
Symptomatic, in bed &gt; 50% of the day but not bedridden
Bedridden
Dead</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="239"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Federation of Gynecology and Obstetrics (FIGO) Stage at Initial Surgery</title>
          <description>Ic: Tumor is either Stage IA or IB level but the capsule is ruptured or there is tumor on the ovarian surface or malignant cells are present in ascites or washings.
II: Tumor involves one or both ovaries with pelvic extension
III: Tumor involving one or both ovaries, with microscopically confirmed peritoneal metastases outside the pelvis and/or regional lymph node metastases
IV: Distant metastases (Excludes peritoneal metastases)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage Ic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="284"/>
                    <measurement group_id="B2" value="289"/>
                    <measurement group_id="B3" value="573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mucinous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="283"/>
                    <measurement group_id="B2" value="276"/>
                    <measurement group_id="B3" value="559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endometroid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Undifferentiated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clear Cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Epithelial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transitional Cell</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant Brenner's Tumor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adenocarcinoma Not Otherwise Specified (NOS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Volume of Residual Tumor Following Debulking Surgery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 2 centimeters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="309"/>
                    <measurement group_id="B2" value="314"/>
                    <measurement group_id="B3" value="623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 2 centimeters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CA-125 Units per milliliter at Baseline for All Patients</title>
          <description>Cancer Antigen 125, units per milliliter</description>
          <units>units per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="492.772" spread="1138.556"/>
                    <measurement group_id="B2" value="479.854" spread="1117.040"/>
                    <measurement group_id="B3" value="486.329" spread="1127.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>Progression free survival was defined as the duration from the date of randomization to the first date of documented disease progression or death from any cause. Tumor assessments were performed every three 21-day cycles during induction and crossover. Progression free survival was censored at the date of the last follow-up visit for participants who were still alive and who had not progressed. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.</description>
        <time_frame>Baseline to measured progressive disease or death up to 82 months</time_frame>
        <population>Intent to treat (ITT) population, which includes all randomized participants. 3 participants in the Gemcitabine/Carboplatin treatment sequence were excluded due to missing data, and 1 participant in the Paclitaxel/Carboplatin treatment sequence was excluded for missing data. G/C Arm: 292 events, 122 censored. P/C Arm: 279 events, 134 censored.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine/Carboplatin</title>
            <description>Induction: Gemcitabine 1000 mg/m^2 Days 1 and 8 followed by Carboplatin Area Under the Curve (AUC) 5 Day 1; every 21-days.
Consolidation (gemcitabine to paclitaxel): Paclitaxel 135 mg/m^2 Intravenous Piggy-Back (IVPB), 3 hours every 28 days for 12 cycles (one year).
Paclitaxel (crossover): Single agent Paclitaxel 175 mg/m^2 day 1 to be repeated every 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel/Carboplatin</title>
            <description>Induction: Paclitaxel 175 mg/m^2 and Carboplatin AUC 6 Day 1, every 21 days. Consolidation (paclitaxel to paclitaxel): Paclitaxel 135 mg/m^2 IVPB, 3 hours every 28 days for 12 cycles (one year).
Gemcitabine (crossover): Single agent Gemcitabine 1000 mg/m^2 days 1, 8 to be repeated every 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>Progression free survival was defined as the duration from the date of randomization to the first date of documented disease progression or death from any cause. Tumor assessments were performed every three 21-day cycles during induction and crossover. Progression free survival was censored at the date of the last follow-up visit for participants who were still alive and who had not progressed. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.</description>
          <population>Intent to treat (ITT) population, which includes all randomized participants. 3 participants in the Gemcitabine/Carboplatin treatment sequence were excluded due to missing data, and 1 participant in the Paclitaxel/Carboplatin treatment sequence was excluded for missing data. G/C Arm: 292 events, 122 censored. P/C Arm: 279 events, 134 censored.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="414"/>
                <count group_id="O2" value="413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="17.9" upper_limit="22.2"/>
                    <measurement group_id="O2" value="22.2" lower_limit="19.0" upper_limit="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Using a two-sided log-rank test with a Type I error of 0.05, 636 events for PFS out of the 919 patients would give an 80% statistical power under the alternative hypothesis that the hazard ratio of the G/C arm versus the P/C arm was 0.08.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.199</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Response (Response Rate)</title>
        <description>Response rate (RR) = proportion of participants with best overall Complete Response (CR: disappearance of all target lesions [TL]) or Partial Response (PR: 30% decrease in sum of longest diameter of TL). Induction therapy RR = number of participants with CR or PR during induction divided by number of participants with measurable disease at baseline (TL measurement during screening). Crossover therapy RR = number of participants with CR or PR during crossover divided by number of participants with measurable disease at baseline (latest TL measurement by first dose date of crossover therapy).</description>
        <time_frame>Baseline to measured progressive disease up to 82 months</time_frame>
        <population>All ITT participants with measurable disease at baseline (screening) for induction period; all ITT participants who crossed over to single agent therapy and had measurable disease before or at crossover for crossover period. Participants in consolidation therapy achieved CR during induction therapy and were not included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine/Carboplatin (Induction)</title>
            <description>Gemcitabine 1000 milligrams per meter square (mg/m^2) Day 1, Day 8, Carboplatin AUC 5 Day 1, six 21-day cycles</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel/Carboplatin (Induction)</title>
            <description>Paclitaxel 175 milligrams per meter square (mg/m^2) administered intravenously (IV) Day 1 Carboplatin AUC 6 Day 1, six 21-day cycles</description>
          </group>
          <group group_id="O3">
            <title>Gemcitabine (Crossover)</title>
            <description>Crossover (From Paclitaxel to Gemcitabine) - If no complete response on Paclitaxel, patient crossed over to receive Gemcitabine 1000 mg/m^2, IV, day 1 and day 8 q 21 days until complete response, disease progression or unacceptable toxicity</description>
          </group>
          <group group_id="O4">
            <title>Paclitaxel (Crossover)</title>
            <description>Crossover (From Gemcitabine to Paclitaxel) - If no complete response on Gemcitabine, patient crossed over to receive Paclitaxel 175 mg/m^2, IV, day 1, q 21 days until complete response, disease progression or unacceptable toxicity</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Response (Response Rate)</title>
          <description>Response rate (RR) = proportion of participants with best overall Complete Response (CR: disappearance of all target lesions [TL]) or Partial Response (PR: 30% decrease in sum of longest diameter of TL). Induction therapy RR = number of participants with CR or PR during induction divided by number of participants with measurable disease at baseline (TL measurement during screening). Crossover therapy RR = number of participants with CR or PR during crossover divided by number of participants with measurable disease at baseline (latest TL measurement by first dose date of crossover therapy).</description>
          <population>All ITT participants with measurable disease at baseline (screening) for induction period; all ITT participants who crossed over to single agent therapy and had measurable disease before or at crossover for crossover period. Participants in consolidation therapy achieved CR during induction therapy and were not included in analysis.</population>
          <units>proportion of responders</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.676" lower_limit="0.638" upper_limit="0.798"/>
                    <measurement group_id="O2" value="0.711" lower_limit="0.651" upper_limit="0.822"/>
                    <measurement group_id="O3" value="0.357" lower_limit="0.194" upper_limit="0.576"/>
                    <measurement group_id="O4" value="0.303" lower_limit="0.161" upper_limit="0.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.771</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.784</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure</title>
        <description>Time to treatment failure was defined as the duration from date of randomization to the date of the first of the following events: early discontinuation of study therapy; progression of disease, or death due to any cause. Time to treatment failure will be censored at the date of the last follow-up visit for participants who did not discontinue early, who are still alive, and who have not progressed. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.</description>
        <time_frame>Baseline to stopping treatment up to 82 months</time_frame>
        <population>Intent to treat (ITT) population, which includes all randomized participants. 3 participants in the Gemcitabine/Carboplatin treatment sequence were excluded due to missing data, and 1 participant in the Paclitaxel/Carboplatin treatment sequence was excluded for missing data. G/C Arm: 336 events, 78 censored. P/C Arm: 330 events, 83 censored.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine/Carboplatin</title>
            <description>Induction: Gemcitabine 1000 mg/m^2 Days 1 and 8 followed by Carboplatin Area Under the Curve (AUC) 5 Day 1; every 21-days.
Consolidation (gemcitabine to paclitaxel): Paclitaxel 135 mg/m^2 Intravenous Piggy-Back (IVPB), 3 hours every 28 days for 12 cycles (one year).
Paclitaxel (crossover): Single agent Paclitaxel 175 mg/m^2 day 1 to be repeated every 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel/Carboplatin</title>
            <description>Induction: Paclitaxel 175 mg/m^2 and Carboplatin AUC 6 Day 1, every 21 days. Consolidation (paclitaxel to paclitaxel): Paclitaxel 135 mg/m^2 IVPB, 3 hours every 28 days for 12 cycles (one year).
Gemcitabine (crossover): Single agent Gemcitabine 1000 mg/m^2 days 1, 8 to be repeated every 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure</title>
          <description>Time to treatment failure was defined as the duration from date of randomization to the date of the first of the following events: early discontinuation of study therapy; progression of disease, or death due to any cause. Time to treatment failure will be censored at the date of the last follow-up visit for participants who did not discontinue early, who are still alive, and who have not progressed. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.</description>
          <population>Intent to treat (ITT) population, which includes all randomized participants. 3 participants in the Gemcitabine/Carboplatin treatment sequence were excluded due to missing data, and 1 participant in the Paclitaxel/Carboplatin treatment sequence was excluded for missing data. G/C Arm: 336 events, 78 censored. P/C Arm: 330 events, 83 censored.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="414"/>
                <count group_id="O2" value="413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="11.7" upper_limit="15.1"/>
                    <measurement group_id="O2" value="13.1" lower_limit="11.4" upper_limit="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.621</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival is defined as the duration from baseline to death. For participants who are still alive at the data cut-off date, survival will be censored at the last contact date. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.</description>
        <time_frame>Baseline to death from any cause up to 82 months</time_frame>
        <population>Intent to treat (ITT) population, which includes all randomized participants. 3 participants in the Gemcitabine/Carboplatin treatment sequence were excluded due to missing data, and 1 participant in the Paclitaxel/Carboplatin treatment sequence was excluded for missing data. G/C Arm: 194 events, 220 censored. P/C Arm: 159 events, 254 censored.</population>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine/Carboplatin</title>
            <description>Induction: Gemcitabine 1000 mg/m^2 Days 1 and 8 followed by Carboplatin Area Under the Curve (AUC) 5 Day 1; every 21-days.
Consolidation (gemcitabine to paclitaxel): Paclitaxel 135 mg/m^2 Intravenous Piggy-Back (IVPB), 3 hours every 28 days for 12 cycles (one year).
Paclitaxel (crossover): Single agent Paclitaxel 175 mg/m^2 day 1 to be repeated every 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Paclitaxel/Carboplatin</title>
            <description>Induction: Paclitaxel 175 mg/m^2 and Carboplatin AUC 6 Day 1, every 21 days. Consolidation (paclitaxel to paclitaxel): Paclitaxel 135 mg/m^2 IVPB, 3 hours every 28 days for 12 cycles (one year).
Gemcitabine (crossover): Single agent Gemcitabine 1000 mg/m^2 days 1, 8 to be repeated every 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival is defined as the duration from baseline to death. For participants who are still alive at the data cut-off date, survival will be censored at the last contact date. Results are presented as a comparison between the two study treatment sequences (induction therapy followed by elective consolidation or crossover therapy) rather than the two induction therapies.</description>
          <population>Intent to treat (ITT) population, which includes all randomized participants. 3 participants in the Gemcitabine/Carboplatin treatment sequence were excluded due to missing data, and 1 participant in the Paclitaxel/Carboplatin treatment sequence was excluded for missing data. G/C Arm: 194 events, 220 censored. P/C Arm: 159 events, 254 censored.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="414"/>
                <count group_id="O2" value="413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8" lower_limit="38.8" upper_limit="48.4"/>
                    <measurement group_id="O2" value="57.3" lower_limit="48.5" upper_limit="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>A participant was randomized to P/C but treated with G/C, and thus included in the P/C arm ITT population (disposition and efficacy tables) and included in the G/C arm of treated population (AE tables). This results in an inconsistency between number of participants analyzed and participant flow module.</desc>
      <group_list>
        <group group_id="E1">
          <title>Gemcitabine/Carboplatin Induction</title>
          <description>Gemcitabine 1000 milligrams per meter square (mg/m2) Day 1, Day 8, Carboplatin AUC 5 Day 1, 6 21 day cycles</description>
        </group>
        <group group_id="E2">
          <title>Paclitaxel/Carboplatin Induction</title>
          <description>Paclitaxel 175 milligrams per meter square (mg/m2) administered intravenously (IV) Day 1 Carboplatin AUC 6 Day 1, 6 21 day cycles</description>
        </group>
        <group group_id="E3">
          <title>Consolidation (Gemcitabine to Paclitaxel)</title>
          <description>Paclitaxel 135mg/m2 IV/3 hours every 28 days for 12 cycles (one year).</description>
        </group>
        <group group_id="E4">
          <title>Consolidation (Paclitaxel to Paclitaxel)</title>
          <description>Paclitaxel 135mg/m2 IV/3 hours every 28 days for 12 cycles (one year).</description>
        </group>
        <group group_id="E5">
          <title>Crossover (Paclitaxel to Gemcitabine)</title>
          <description>Single agent Gemcitabine 1000mg/m2 IV, Day 1, Day 8 to be repeated every 21 days.</description>
        </group>
        <group group_id="E6">
          <title>Crossover (Gemcitabine to Paclitaxel)</title>
          <description>Single agent Paclitaxel 175mg/m2 IV Day 1 to be repeated every 21 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="412"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="412"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="412"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="412"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Retroperitoneum cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="408"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="412"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="412"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Sensation of pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Catheter bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Catheter sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pneumonia primary atypical</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis septic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="412"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Infection/febrile neutropenia</sub_title>
                <description>The adverse event term and organ system were not coded via MedDRA. The organ system was provide as a requirement to release the record.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Drug administration error</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Absolute neutrophil count/absolute granulocyte count</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="412"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Haematocrit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="412"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Platelet count</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="53" subjects_affected="43" subjects_at_risk="412"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>White blood cells</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hematologic</sub_title>
                <description>The adverse event term and organ system were not coded via MedDRA. The organ system was provide as a requirement to release the record.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="412"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Costovertebral angle tenderness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Vaginal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Respiratory depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pain management</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="412"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="404" subjects_at_risk="412"/>
                <counts group_id="E2" subjects_affected="394" subjects_at_risk="408"/>
                <counts group_id="E3" subjects_affected="157" subjects_at_risk="169"/>
                <counts group_id="E4" subjects_affected="170" subjects_at_risk="183"/>
                <counts group_id="E5" subjects_affected="76" subjects_at_risk="78"/>
                <counts group_id="E6" subjects_affected="73" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="9" subjects_at_risk="412"/>
                <counts group_id="E2" events="25" subjects_affected="10" subjects_at_risk="408"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E4" events="9" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E5" events="10" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="68" subjects_affected="22" subjects_at_risk="412"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="408"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="7" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="31" subjects_affected="18" subjects_at_risk="412"/>
                <counts group_id="E2" events="39" subjects_affected="22" subjects_at_risk="408"/>
                <counts group_id="E3" events="26" subjects_affected="8" subjects_at_risk="169"/>
                <counts group_id="E4" events="39" subjects_affected="14" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="8" subjects_affected="2" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="26" subjects_affected="15" subjects_at_risk="412"/>
                <counts group_id="E2" events="50" subjects_affected="26" subjects_at_risk="408"/>
                <counts group_id="E3" events="26" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E4" events="33" subjects_affected="15" subjects_at_risk="183"/>
                <counts group_id="E5" events="6" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="412"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="408"/>
                <counts group_id="E3" events="15" subjects_affected="8" subjects_at_risk="169"/>
                <counts group_id="E4" events="23" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="9" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="32" subjects_affected="21" subjects_at_risk="412"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="408"/>
                <counts group_id="E3" events="24" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E4" events="18" subjects_affected="13" subjects_at_risk="183"/>
                <counts group_id="E5" events="12" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E6" events="10" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="168" subjects_affected="88" subjects_at_risk="412"/>
                <counts group_id="E2" events="148" subjects_affected="92" subjects_at_risk="408"/>
                <counts group_id="E3" events="76" subjects_affected="29" subjects_at_risk="169"/>
                <counts group_id="E4" events="68" subjects_affected="32" subjects_at_risk="183"/>
                <counts group_id="E5" events="26" subjects_affected="14" subjects_at_risk="78"/>
                <counts group_id="E6" events="30" subjects_affected="16" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="27" subjects_affected="21" subjects_at_risk="412"/>
                <counts group_id="E2" events="24" subjects_affected="16" subjects_at_risk="408"/>
                <counts group_id="E3" events="13" subjects_affected="8" subjects_at_risk="169"/>
                <counts group_id="E4" events="10" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="400" subjects_affected="173" subjects_at_risk="412"/>
                <counts group_id="E2" events="391" subjects_affected="170" subjects_at_risk="408"/>
                <counts group_id="E3" events="154" subjects_affected="54" subjects_at_risk="169"/>
                <counts group_id="E4" events="178" subjects_affected="62" subjects_at_risk="183"/>
                <counts group_id="E5" events="66" subjects_affected="31" subjects_at_risk="78"/>
                <counts group_id="E6" events="60" subjects_affected="25" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="145" subjects_affected="83" subjects_at_risk="412"/>
                <counts group_id="E2" events="187" subjects_affected="97" subjects_at_risk="408"/>
                <counts group_id="E3" events="107" subjects_affected="43" subjects_at_risk="169"/>
                <counts group_id="E4" events="111" subjects_affected="43" subjects_at_risk="183"/>
                <counts group_id="E5" events="17" subjects_affected="12" subjects_at_risk="78"/>
                <counts group_id="E6" events="19" subjects_affected="9" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="412"/>
                <counts group_id="E2" events="26" subjects_affected="17" subjects_at_risk="408"/>
                <counts group_id="E3" events="24" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E4" events="20" subjects_affected="14" subjects_at_risk="183"/>
                <counts group_id="E5" events="6" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="504" subjects_affected="213" subjects_at_risk="412"/>
                <counts group_id="E2" events="506" subjects_affected="205" subjects_at_risk="408"/>
                <counts group_id="E3" events="191" subjects_affected="67" subjects_at_risk="169"/>
                <counts group_id="E4" events="110" subjects_affected="46" subjects_at_risk="183"/>
                <counts group_id="E5" events="67" subjects_affected="32" subjects_at_risk="78"/>
                <counts group_id="E6" events="48" subjects_affected="21" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="33" subjects_affected="25" subjects_at_risk="412"/>
                <counts group_id="E2" events="40" subjects_affected="23" subjects_at_risk="408"/>
                <counts group_id="E3" events="18" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E4" events="24" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="7" subjects_affected="3" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="146" subjects_affected="95" subjects_at_risk="412"/>
                <counts group_id="E2" events="154" subjects_affected="95" subjects_at_risk="408"/>
                <counts group_id="E3" events="24" subjects_affected="19" subjects_at_risk="169"/>
                <counts group_id="E4" events="20" subjects_affected="12" subjects_at_risk="183"/>
                <counts group_id="E5" events="22" subjects_affected="14" subjects_at_risk="78"/>
                <counts group_id="E6" events="20" subjects_affected="9" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="28" subjects_at_risk="412"/>
                <counts group_id="E2" events="41" subjects_affected="34" subjects_at_risk="408"/>
                <counts group_id="E3" events="12" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E4" events="15" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="948" subjects_affected="281" subjects_at_risk="412"/>
                <counts group_id="E2" events="912" subjects_affected="279" subjects_at_risk="408"/>
                <counts group_id="E3" events="531" subjects_affected="108" subjects_at_risk="169"/>
                <counts group_id="E4" events="558" subjects_affected="119" subjects_at_risk="183"/>
                <counts group_id="E5" events="217" subjects_affected="56" subjects_at_risk="78"/>
                <counts group_id="E6" events="160" subjects_affected="40" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="31" subjects_affected="20" subjects_at_risk="412"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="408"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E4" events="18" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="84" subjects_affected="46" subjects_at_risk="412"/>
                <counts group_id="E2" events="53" subjects_affected="33" subjects_at_risk="408"/>
                <counts group_id="E3" events="50" subjects_affected="18" subjects_at_risk="169"/>
                <counts group_id="E4" events="64" subjects_affected="21" subjects_at_risk="183"/>
                <counts group_id="E5" events="12" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E6" events="8" subjects_affected="6" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="31" subjects_affected="25" subjects_at_risk="412"/>
                <counts group_id="E2" events="59" subjects_affected="38" subjects_at_risk="408"/>
                <counts group_id="E3" events="76" subjects_affected="36" subjects_at_risk="169"/>
                <counts group_id="E4" events="43" subjects_affected="26" subjects_at_risk="183"/>
                <counts group_id="E5" events="12" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="47" subjects_affected="34" subjects_at_risk="412"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="408"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="78"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="412"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="408"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="412"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="408"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E4" events="14" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="412"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="408"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="183"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="31" subjects_affected="28" subjects_at_risk="412"/>
                <counts group_id="E2" events="41" subjects_affected="31" subjects_at_risk="408"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E4" events="19" subjects_affected="14" subjects_at_risk="183"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="48" subjects_affected="31" subjects_at_risk="412"/>
                <counts group_id="E2" events="28" subjects_affected="15" subjects_at_risk="408"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E4" events="19" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" events="53" subjects_affected="24" subjects_at_risk="412"/>
                <counts group_id="E2" events="33" subjects_affected="19" subjects_at_risk="408"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E4" events="21" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E5" events="12" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="120" subjects_affected="64" subjects_at_risk="412"/>
                <counts group_id="E2" events="46" subjects_affected="27" subjects_at_risk="408"/>
                <counts group_id="E3" events="27" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E4" events="17" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E5" events="20" subjects_affected="11" subjects_at_risk="78"/>
                <counts group_id="E6" events="10" subjects_affected="2" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Anc/agc</sub_title>
                <counts group_id="E1" events="1638" subjects_affected="378" subjects_at_risk="412"/>
                <counts group_id="E2" events="1531" subjects_affected="361" subjects_at_risk="408"/>
                <counts group_id="E3" events="314" subjects_affected="88" subjects_at_risk="169"/>
                <counts group_id="E4" events="325" subjects_affected="93" subjects_at_risk="183"/>
                <counts group_id="E5" events="246" subjects_affected="68" subjects_at_risk="78"/>
                <counts group_id="E6" events="173" subjects_affected="47" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="100" subjects_affected="58" subjects_at_risk="412"/>
                <counts group_id="E2" events="36" subjects_affected="21" subjects_at_risk="408"/>
                <counts group_id="E3" events="21" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E4" events="23" subjects_affected="13" subjects_at_risk="183"/>
                <counts group_id="E5" events="19" subjects_affected="12" subjects_at_risk="78"/>
                <counts group_id="E6" events="8" subjects_affected="3" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" events="39" subjects_affected="18" subjects_at_risk="412"/>
                <counts group_id="E2" events="36" subjects_affected="17" subjects_at_risk="408"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" events="7" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase</sub_title>
                <counts group_id="E1" events="51" subjects_affected="23" subjects_at_risk="412"/>
                <counts group_id="E2" events="32" subjects_affected="20" subjects_at_risk="408"/>
                <counts group_id="E3" events="19" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E4" events="12" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E5" events="7" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="103" subjects_affected="52" subjects_at_risk="412"/>
                <counts group_id="E2" events="68" subjects_affected="37" subjects_at_risk="408"/>
                <counts group_id="E3" events="33" subjects_affected="13" subjects_at_risk="169"/>
                <counts group_id="E4" events="38" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E5" events="11" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E6" events="12" subjects_affected="7" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Blood glucose</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="412"/>
                <counts group_id="E2" events="32" subjects_affected="22" subjects_at_risk="408"/>
                <counts group_id="E3" events="17" subjects_affected="12" subjects_at_risk="169"/>
                <counts group_id="E4" events="46" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="10" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="93" subjects_affected="46" subjects_at_risk="412"/>
                <counts group_id="E2" events="108" subjects_affected="50" subjects_at_risk="408"/>
                <counts group_id="E3" events="79" subjects_affected="26" subjects_at_risk="169"/>
                <counts group_id="E4" events="55" subjects_affected="21" subjects_at_risk="183"/>
                <counts group_id="E5" events="13" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E6" events="18" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" events="28" subjects_affected="14" subjects_at_risk="412"/>
                <counts group_id="E2" events="41" subjects_affected="23" subjects_at_risk="408"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" events="39" subjects_affected="19" subjects_at_risk="412"/>
                <counts group_id="E2" events="28" subjects_affected="18" subjects_at_risk="408"/>
                <counts group_id="E3" events="53" subjects_affected="22" subjects_at_risk="169"/>
                <counts group_id="E4" events="20" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="21" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Carbon dioxide increased</sub_title>
                <counts group_id="E1" events="41" subjects_affected="18" subjects_at_risk="412"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="408"/>
                <counts group_id="E3" events="33" subjects_affected="12" subjects_at_risk="169"/>
                <counts group_id="E4" events="11" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Haematocrit</sub_title>
                <counts group_id="E1" events="42" subjects_affected="24" subjects_at_risk="412"/>
                <counts group_id="E2" events="33" subjects_affected="17" subjects_at_risk="408"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="12" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E5" events="9" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="1830" subjects_affected="385" subjects_at_risk="412"/>
                <counts group_id="E2" events="1436" subjects_affected="352" subjects_at_risk="408"/>
                <counts group_id="E3" events="338" subjects_affected="83" subjects_at_risk="169"/>
                <counts group_id="E4" events="375" subjects_affected="103" subjects_at_risk="183"/>
                <counts group_id="E5" events="270" subjects_affected="66" subjects_at_risk="78"/>
                <counts group_id="E6" events="201" subjects_affected="54" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="412"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="408"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" events="8" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="412"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="408"/>
                <counts group_id="E3" events="12" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="11" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1550" subjects_affected="379" subjects_at_risk="412"/>
                <counts group_id="E2" events="631" subjects_affected="233" subjects_at_risk="408"/>
                <counts group_id="E3" events="110" subjects_affected="36" subjects_at_risk="169"/>
                <counts group_id="E4" events="72" subjects_affected="23" subjects_at_risk="183"/>
                <counts group_id="E5" events="216" subjects_affected="61" subjects_at_risk="78"/>
                <counts group_id="E6" events="31" subjects_affected="16" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Protein total decreased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="412"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="408"/>
                <counts group_id="E3" events="17" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>White blood cells</sub_title>
                <counts group_id="E1" events="1714" subjects_affected="380" subjects_at_risk="412"/>
                <counts group_id="E2" events="1507" subjects_affected="350" subjects_at_risk="408"/>
                <counts group_id="E3" events="423" subjects_affected="88" subjects_at_risk="169"/>
                <counts group_id="E4" events="442" subjects_affected="101" subjects_at_risk="183"/>
                <counts group_id="E5" events="247" subjects_affected="68" subjects_at_risk="78"/>
                <counts group_id="E6" events="208" subjects_affected="49" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="67" subjects_affected="37" subjects_at_risk="412"/>
                <counts group_id="E2" events="45" subjects_affected="31" subjects_at_risk="408"/>
                <counts group_id="E3" events="10" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="60" subjects_affected="24" subjects_at_risk="412"/>
                <counts group_id="E2" events="33" subjects_affected="15" subjects_at_risk="408"/>
                <counts group_id="E3" events="100" subjects_affected="26" subjects_at_risk="169"/>
                <counts group_id="E4" events="88" subjects_affected="31" subjects_at_risk="183"/>
                <counts group_id="E5" events="16" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E6" events="25" subjects_affected="5" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="82" subjects_affected="49" subjects_at_risk="412"/>
                <counts group_id="E2" events="99" subjects_affected="57" subjects_at_risk="408"/>
                <counts group_id="E3" events="22" subjects_affected="13" subjects_at_risk="169"/>
                <counts group_id="E4" events="8" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E5" events="15" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E6" events="25" subjects_affected="8" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="111" subjects_affected="45" subjects_at_risk="412"/>
                <counts group_id="E2" events="158" subjects_affected="72" subjects_at_risk="408"/>
                <counts group_id="E3" events="150" subjects_affected="36" subjects_at_risk="169"/>
                <counts group_id="E4" events="152" subjects_affected="42" subjects_at_risk="183"/>
                <counts group_id="E5" events="23" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E6" events="53" subjects_affected="16" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="17" subjects_at_risk="412"/>
                <counts group_id="E2" events="18" subjects_affected="11" subjects_at_risk="408"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="7" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="14" subjects_at_risk="412"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="408"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="47" subjects_affected="29" subjects_at_risk="412"/>
                <counts group_id="E2" events="29" subjects_affected="20" subjects_at_risk="408"/>
                <counts group_id="E3" events="13" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E4" events="18" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="13" subjects_affected="8" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="412"/>
                <counts group_id="E2" events="24" subjects_affected="14" subjects_at_risk="408"/>
                <counts group_id="E3" events="9" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E4" events="15" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="7" subjects_affected="4" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="86" subjects_affected="48" subjects_at_risk="412"/>
                <counts group_id="E2" events="247" subjects_affected="108" subjects_at_risk="408"/>
                <counts group_id="E3" events="192" subjects_affected="66" subjects_at_risk="169"/>
                <counts group_id="E4" events="149" subjects_affected="53" subjects_at_risk="183"/>
                <counts group_id="E5" events="32" subjects_affected="16" subjects_at_risk="78"/>
                <counts group_id="E6" events="62" subjects_affected="25" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="8" subjects_at_risk="412"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="408"/>
                <counts group_id="E3" events="10" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E4" events="33" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E5" events="6" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="72" subjects_affected="47" subjects_at_risk="412"/>
                <counts group_id="E2" events="81" subjects_affected="42" subjects_at_risk="408"/>
                <counts group_id="E3" events="37" subjects_affected="19" subjects_at_risk="169"/>
                <counts group_id="E4" events="76" subjects_affected="30" subjects_at_risk="183"/>
                <counts group_id="E5" events="12" subjects_affected="9" subjects_at_risk="78"/>
                <counts group_id="E6" events="12" subjects_affected="8" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="14" subjects_at_risk="412"/>
                <counts group_id="E2" events="45" subjects_affected="33" subjects_at_risk="408"/>
                <counts group_id="E3" events="38" subjects_affected="16" subjects_at_risk="169"/>
                <counts group_id="E4" events="15" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="9" subjects_affected="6" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="30" subjects_affected="15" subjects_at_risk="412"/>
                <counts group_id="E2" events="46" subjects_affected="26" subjects_at_risk="408"/>
                <counts group_id="E3" events="22" subjects_affected="8" subjects_at_risk="169"/>
                <counts group_id="E4" events="69" subjects_affected="18" subjects_at_risk="183"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="41" subjects_affected="25" subjects_at_risk="412"/>
                <counts group_id="E2" events="97" subjects_affected="55" subjects_at_risk="408"/>
                <counts group_id="E3" events="91" subjects_affected="37" subjects_at_risk="169"/>
                <counts group_id="E4" events="53" subjects_affected="25" subjects_at_risk="183"/>
                <counts group_id="E5" events="17" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E6" events="13" subjects_affected="8" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="62" subjects_affected="36" subjects_at_risk="412"/>
                <counts group_id="E2" events="220" subjects_affected="100" subjects_at_risk="408"/>
                <counts group_id="E3" events="130" subjects_affected="44" subjects_at_risk="169"/>
                <counts group_id="E4" events="103" subjects_affected="38" subjects_at_risk="183"/>
                <counts group_id="E5" events="23" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E6" events="40" subjects_affected="17" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="45" subjects_affected="27" subjects_at_risk="412"/>
                <counts group_id="E2" events="75" subjects_affected="49" subjects_at_risk="408"/>
                <counts group_id="E3" events="45" subjects_affected="18" subjects_at_risk="169"/>
                <counts group_id="E4" events="62" subjects_affected="18" subjects_at_risk="183"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="65" subjects_affected="44" subjects_at_risk="412"/>
                <counts group_id="E2" events="52" subjects_affected="34" subjects_at_risk="408"/>
                <counts group_id="E3" events="22" subjects_affected="11" subjects_at_risk="169"/>
                <counts group_id="E4" events="18" subjects_affected="14" subjects_at_risk="183"/>
                <counts group_id="E5" events="10" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E6" events="9" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="82" subjects_affected="40" subjects_at_risk="412"/>
                <counts group_id="E2" events="75" subjects_affected="39" subjects_at_risk="408"/>
                <counts group_id="E3" events="41" subjects_affected="20" subjects_at_risk="169"/>
                <counts group_id="E4" events="28" subjects_affected="15" subjects_at_risk="183"/>
                <counts group_id="E5" events="7" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="14" subjects_affected="6" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="25" subjects_at_risk="412"/>
                <counts group_id="E2" events="93" subjects_affected="53" subjects_at_risk="408"/>
                <counts group_id="E3" events="70" subjects_affected="29" subjects_at_risk="169"/>
                <counts group_id="E4" events="103" subjects_affected="33" subjects_at_risk="183"/>
                <counts group_id="E5" events="14" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E6" events="32" subjects_affected="12" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="28" subjects_affected="15" subjects_at_risk="412"/>
                <counts group_id="E2" events="140" subjects_affected="65" subjects_at_risk="408"/>
                <counts group_id="E3" events="122" subjects_affected="39" subjects_at_risk="169"/>
                <counts group_id="E4" events="183" subjects_affected="51" subjects_at_risk="183"/>
                <counts group_id="E5" events="20" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E6" events="64" subjects_affected="19" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="58" subjects_affected="22" subjects_at_risk="412"/>
                <counts group_id="E2" events="190" subjects_affected="99" subjects_at_risk="408"/>
                <counts group_id="E3" events="207" subjects_affected="62" subjects_at_risk="169"/>
                <counts group_id="E4" events="211" subjects_affected="68" subjects_at_risk="183"/>
                <counts group_id="E5" events="39" subjects_affected="17" subjects_at_risk="78"/>
                <counts group_id="E6" events="60" subjects_affected="23" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="28" subjects_at_risk="412"/>
                <counts group_id="E2" events="191" subjects_affected="88" subjects_at_risk="408"/>
                <counts group_id="E3" events="94" subjects_affected="38" subjects_at_risk="169"/>
                <counts group_id="E4" events="165" subjects_affected="42" subjects_at_risk="183"/>
                <counts group_id="E5" events="27" subjects_affected="15" subjects_at_risk="78"/>
                <counts group_id="E6" events="19" subjects_affected="9" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="42" subjects_affected="20" subjects_at_risk="412"/>
                <counts group_id="E2" events="162" subjects_affected="61" subjects_at_risk="408"/>
                <counts group_id="E3" events="91" subjects_affected="26" subjects_at_risk="169"/>
                <counts group_id="E4" events="186" subjects_affected="43" subjects_at_risk="183"/>
                <counts group_id="E5" events="22" subjects_affected="9" subjects_at_risk="78"/>
                <counts group_id="E6" events="48" subjects_affected="11" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Neurology</sub_title>
                <description>The adverse event term and organ system were not coded via MedDRA. The organ system was provide as a requirement to release the record.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E2" events="17" subjects_affected="10" subjects_at_risk="408"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E4" events="28" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="20" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>The adverse event term and organ system were not coded via MedDRA. The organ system was provide as a requirement to release the record.</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="412"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="408"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="15" subjects_affected="5" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="63" subjects_affected="32" subjects_at_risk="412"/>
                <counts group_id="E2" events="50" subjects_affected="35" subjects_at_risk="408"/>
                <counts group_id="E3" events="38" subjects_affected="19" subjects_at_risk="169"/>
                <counts group_id="E4" events="35" subjects_affected="15" subjects_at_risk="183"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="11" subjects_affected="8" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="92" subjects_affected="47" subjects_at_risk="412"/>
                <counts group_id="E2" events="100" subjects_affected="50" subjects_at_risk="408"/>
                <counts group_id="E3" events="75" subjects_affected="27" subjects_at_risk="169"/>
                <counts group_id="E4" events="132" subjects_affected="36" subjects_at_risk="183"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="33" subjects_affected="10" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="92" subjects_affected="42" subjects_at_risk="412"/>
                <counts group_id="E2" events="150" subjects_affected="73" subjects_at_risk="408"/>
                <counts group_id="E3" events="99" subjects_affected="32" subjects_at_risk="169"/>
                <counts group_id="E4" events="77" subjects_affected="23" subjects_at_risk="183"/>
                <counts group_id="E5" events="12" subjects_affected="9" subjects_at_risk="78"/>
                <counts group_id="E6" events="9" subjects_affected="7" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="412"/>
                <counts group_id="E2" events="26" subjects_affected="21" subjects_at_risk="408"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="7" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="32" subjects_affected="18" subjects_at_risk="412"/>
                <counts group_id="E2" events="38" subjects_affected="22" subjects_at_risk="408"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E6" events="6" subjects_affected="3" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E2" events="12" subjects_affected="8" subjects_at_risk="408"/>
                <counts group_id="E3" events="13" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E4" events="34" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="412"/>
                <counts group_id="E2" events="46" subjects_affected="22" subjects_at_risk="408"/>
                <counts group_id="E3" events="20" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E4" events="24" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="57" subjects_affected="37" subjects_at_risk="412"/>
                <counts group_id="E2" events="45" subjects_affected="29" subjects_at_risk="408"/>
                <counts group_id="E3" events="49" subjects_affected="22" subjects_at_risk="169"/>
                <counts group_id="E4" events="48" subjects_affected="23" subjects_at_risk="183"/>
                <counts group_id="E5" events="24" subjects_affected="10" subjects_at_risk="78"/>
                <counts group_id="E6" events="21" subjects_affected="5" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="83" subjects_affected="50" subjects_at_risk="412"/>
                <counts group_id="E2" events="99" subjects_affected="67" subjects_at_risk="408"/>
                <counts group_id="E3" events="40" subjects_affected="19" subjects_at_risk="169"/>
                <counts group_id="E4" events="61" subjects_affected="23" subjects_at_risk="183"/>
                <counts group_id="E5" events="14" subjects_affected="11" subjects_at_risk="78"/>
                <counts group_id="E6" events="9" subjects_affected="8" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="55" subjects_affected="31" subjects_at_risk="412"/>
                <counts group_id="E2" events="27" subjects_affected="20" subjects_at_risk="408"/>
                <counts group_id="E3" events="20" subjects_affected="9" subjects_at_risk="169"/>
                <counts group_id="E4" events="31" subjects_affected="13" subjects_at_risk="183"/>
                <counts group_id="E5" events="15" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E6" events="8" subjects_affected="4" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="53" subjects_affected="37" subjects_at_risk="412"/>
                <counts group_id="E2" events="22" subjects_affected="13" subjects_at_risk="408"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="260" subjects_affected="94" subjects_at_risk="412"/>
                <counts group_id="E2" events="917" subjects_affected="249" subjects_at_risk="408"/>
                <counts group_id="E3" events="600" subjects_affected="102" subjects_at_risk="169"/>
                <counts group_id="E4" events="469" subjects_affected="94" subjects_at_risk="183"/>
                <counts group_id="E5" events="117" subjects_affected="42" subjects_at_risk="78"/>
                <counts group_id="E6" events="251" subjects_affected="49" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hypotrichosis</sub_title>
                <counts group_id="E1" events="73" subjects_affected="24" subjects_at_risk="412"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="408"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="32" subjects_affected="18" subjects_at_risk="412"/>
                <counts group_id="E2" events="33" subjects_affected="20" subjects_at_risk="408"/>
                <counts group_id="E3" events="18" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E4" events="14" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="78"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="59" subjects_affected="42" subjects_at_risk="412"/>
                <counts group_id="E2" events="68" subjects_affected="42" subjects_at_risk="408"/>
                <counts group_id="E3" events="50" subjects_affected="30" subjects_at_risk="169"/>
                <counts group_id="E4" events="48" subjects_affected="25" subjects_at_risk="183"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="78"/>
                <counts group_id="E6" events="12" subjects_affected="8" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="412"/>
                <counts group_id="E2" events="22" subjects_affected="11" subjects_at_risk="408"/>
                <counts group_id="E3" events="14" subjects_affected="10" subjects_at_risk="169"/>
                <counts group_id="E4" events="34" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E5" events="4" subjects_affected="1" subjects_at_risk="78"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="77"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="99" subjects_affected="38" subjects_at_risk="412"/>
                <counts group_id="E2" events="145" subjects_affected="60" subjects_at_risk="408"/>
                <counts group_id="E3" events="132" subjects_affected="35" subjects_at_risk="169"/>
                <counts group_id="E4" events="172" subjects_affected="38" subjects_at_risk="183"/>
                <counts group_id="E5" events="31" subjects_affected="11" subjects_at_risk="78"/>
                <counts group_id="E6" events="22" subjects_affected="6" subjects_at_risk="77"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Trial was designed with overall survival as primary endpoint. Enrollment was slower than expected. After 4 years, 919 patients were randomized and in August 2006, protocol was amended: primary endpoint was changed to progression free survival (PFS).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

